Výsledky vyhledávání - "Takekazu Aoyama"

A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer

Autor: Jaime Feliu, Hirokazu Mizuguchi, A. Hontsa, Lukas Makris, Takekazu Aoyama, V. Esko, Anneli Elme, Igor Bondarenko, Udit Verma, Yaroslav Shparyk, M. Abramov, Sergey Lazarev, Maria Alsina, Jaffer A. Ajani, Gerardo Rosati, Kathia Cristina Abdalla, Vera Gorbunova, Fabio Benedetti, N. Otchenash

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology. 28(9)

Background The effect of histology-based treatment regimen on diffuse gastric adenocarcinoma has not been evaluated in clinical trials. This international phase III trial evaluated the efficacy and safety of S-1 (a contemporary oral fluoropyrimidine)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acf897e5696af73bcf14ceb8c1fa3b81
https://pubmed.ncbi.nlm.nih.gov/28911091

Zobrazit plný text záznamu

Abstract CT014: A large phase I study of TAS-114 in combination with S-1 in patients with advanced solid tumors

Autor: Jean-Luc Van Laethem, Christiana Sessa, Kunihiro Yoshisue, Anastasios Stathis, Angelica Fasolo, Lucca Gianni, Alberto Sobrero, Jean-Charles Soria, Antoine Hollebecque, Takekazu Aoyama

Publikováno v: Cancer Research. 78:CT014-CT014

Background: Deoxyuridine triphosphatase (dUTPase) is the key gatekeeper enzyme that inhibits 5-fluorouracil (5-FU) misincorporation into DNA in tumor cells, and its overexpression is associated with resistance to 5-FU-based chemotherapy.1 TAS-114 is

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c46627b527f0f0d0d220a134266ee5cf
https://doi.org/10.1158/1538-7445.am2018-ct014

Zobrazit plný text záznamu

Abstract CT012: Phase I study of TAS-114 in combination with capecitabine in patients with advanced solid tumors

Autor: Ki Y. Chung, Kunihiro Yoshisue, Kathy D. Miller, Takekazu Aoyama, Anthony F. Shields, Patricia LoRusso, Heinz-Josef Lenz

Publikováno v: Cancer Research. 78:CT012-CT012

Background: TAS-114 is a novel dual inhibitor of deoxyuridine triphosphatase and dihydropyrimidine dehydrogenase, and has shown favorable safety and preliminary efficacy in combination with S-1 or capecitabine in patients (pts) with advanced solid tu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c70a362240a3cb6f2f415bcd0d87a135
https://doi.org/10.1158/1538-7445.am2018-ct012

Zobrazit plný text záznamu

Protracted survival after resection of metastatic uveal melanoma

Autor: Faith E. Nathan, Takekazu Aoyama M.D., Francis E. Rosato, Michael J. Mastrangelo, Ernest L. Rosato, David Berd, Jerry A. Shields, Takami Sato, Carol L. Shields

Publikováno v: Cancer. 89:1561-1568

BACKGROUND The objective of this study was to evaluate the usefulness of resection of metastatic uveal melanoma and to analyze the characteristics of patients who may benefit from surgical intervention. PATIENTS AND METHODS Twelve patients underwent

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2af98c63f5580601e48e7aa925e8b5ba
https://doi.org/10.1002/1097-0142(20001001)89:7<1561::aid-cncr21>3.0.co

Zobrazit plný text záznamu

TAS-115, a potent MET/VEGFRs-targeted kinase inhibitor with high tolerability, to suppress NSCLC-driven bone disruption

Autor: Kazuhiko Yonekura, Hidenori Fujita, Kenjiro Ito, Takekazu Aoyama, Toshihiko Doi, Akira Gomori, Akihiro Hashimoto, Yayoi Fujioka, Nobuaki Matsubara, Takamasa Suzuki, Motomu Sakuragi, Yoshikazu Iwasawa

Publikováno v: Journal of Clinical Oncology. 33:e22011-e22011

e22011 Background: Bone metastasis is a crucial issue for patients with late-stage cancer as it impairs QOL and shortens survival. Bisphosphonates, anti-RANKL antibody and 223RaCl2are approved agen...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3852df6ae0d67409542b933d0486e48f
https://doi.org/10.1200/jco.2015.33.15_suppl.e22011

Zobrazit plný text záznamu

Abstract B54: Phase I study of ombrabulin in combination with cisplatin (CDDP) administered every 3 weeks to Japanese patients with advanced solid tumors

Autor: Kei Muro, Kiyohiko Hatake, Masahiro Yokoyama, Keisho Chin, Takashi Ura, Kohei Shitara, Shunji Takahashi, Tomoya Yokota, Takekazu Aoyama, Kenji Nakano

Publikováno v: Molecular Cancer Therapeutics. 10:B54-B54

Background: Ombrabulin, an analog of Combretastatin A4, is a vascular disrupting agent that destroys established tumor vasculature, causing blood perfusion shutdown and tumor necrosis. However, a narrow rim of tumor cells remains at the tumor periphe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c8fbe1af9e49fbe61092b6d5a09e6c01
https://doi.org/10.1158/1535-7163.targ-11-b54

Zobrazit plný text záznamu

Abstract C20: Phase I study of ombrabulin, a vascular disrupting agent (VDA), administered every 3 weeks to Japanese patients with advanced solid tumors

Autor: Takayasu Kurata, Takekazu Aoyama, Junichiro Watanabe, Yasuhito Fujisaka, Nobuyuki Yamamoto, Yusuke Onozawa, Haruyasu Murakami, Hidemi Kiyota, Kazuhiko Nakagawa

Publikováno v: Molecular Cancer Therapeutics. 10:C20-C20

Background: Ombrabulin, an analog of Combretastatin A4, is a vascular disrupting agent that destroys established tumor vasculature, causing blood perfusion shutdown and tumor necrosis. In Caucasian patients (pts), the recommended dose (RD) for ombrab

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3f82fa73219c7010350234b2bf4a69a1
https://doi.org/10.1158/1535-7163.targ-11-c20

Zobrazit plný text záznamu

Noninvasive evaluation of aortocoronary bypass graft patency by contrast-enhanced computed tomography: incrementation mode and dynamic mode

Autor: Michio Kawasuji, Masayuki Suzuki, Takashi Iwa, Takekazu Aoyama

Publikováno v: Japanese circulation journal. 48(7)

Fourty-three coronary bypass graft patients were examined with contrast-enhanced computed tomography (CT) to evaluate bypass graft patency. Six 4.8-second sequential scans with 1.4-second interscan intervals were obtained during the injection of a bo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f583b62401ca7bee22abcc091d78b097
https://pubmed.ncbi.nlm.nih.gov/6332204

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání